Abstract: The present invention relates to biodegradable glitters with enhanced solvent resistance and enhanced temperature stability, and also to the use thereof in cosmetic formulations, coating materials, and plastics; the glitters comprise a foil which comprises cellulose.

Abstract: To provide a novel external skin composition suitable for cell activation. A external skin composition of the present disclosure contains a UV wavelength conversion substance and an alkylene oxide derivative.

Abstract: A composition for dyeing of keratin fibers, containing a) 1,4-diamino-2-methoxymethyl-benzene, b) an oxidative dye coupler or oxidative dye precursor different from the 1,4-diamino-2-methoxymethyl-benzene, and c) a direct dye which is at least one selected from HC Blue 18, HC Red 18, HC Yellow 16, salts thereof, or mixtures thereof. A method for dyeing keratin fibers.

Abstract: An oxidative dyeing composition A for keratin fibers, including a) a salt of 1,4-diamino-2-methoxymethyl-benzene, and c) an alkalizing agent which is at least one selected from inorganic alkalizing agents, organic alkalizing agents, salts thereof, or mixtures thereof. The salt of 1,4-diamino-2-methoxymethyl-benzene is at least one selected from a sulfate salt, a hydrogen sulfate salt, a hydrochloride salt, a hydrobromide salt, a nitrate salt, a phosphate salt, a hydrogen phosphate salt, a dihydrogen phosphate salt, a methosulfate salt, a citrate salt, a succinate salt, a tartrate salt, a lactate salt, a tosylate salt, a benzenesulfonate salt, an acetate salt, or mixtures thereof.

Abstract: The invention relates to oxidative hair treatment agents, in particular bleaching powder and bleaching pastes, comprising a content of biodegradable complexing agents which do not have a strong heating effect even when used on hair with a high metal or heavy metal content, thus gently lightening the hair or dyeing the hair in a lightening manner.

Abstract: Described herein is a perfume composition including at least one sulfur-containing pro-fragrance compound and at least one aldehydic perfumery raw material, where the at least one aldehydic perfumery raw material is present in an amount effective to reduce the formation of hydrogen sulfide from the sulfur-containing pro-fragrance. Also described herein are consumer products including the perfume composition as well as the use of at least one aldehydic perfumery raw material for reducing the formation of hydrogen sulfide from a sulfur-containing pro-fragrance.

Abstract: The present invention relates to a kit for making up keratin materials, in particular the eyebrows and the skin around the eyebrows, comprising, notably in a physiologically acceptable medium: a) a first aqueous “base-coat” makeup composition (A) comprising at least one water-soluble dye; b) a second “top-coat” fixing composition (B) comprising a continuous oily phase containing: i) at least one hydrophobic film-forming polymer other than silicone acrylate copolymers; and ii) at least one volatile hydrocarbon-based oil. The invention also relates to a cosmetic process for making up keratin materials, in particular the eyebrows and the skin around the eyebrows, comprising: at least a first step of applying a first coat of composition (A) as defined previously to said keratin materials, and at least a second step of applying, to the coat formed by composition (A), at least one second coat of composition (B) as defined previously.

Abstract: Colorant Compositions free of cochineal red are described. The colorant compositions mimic the color of cochineal red and they are stable in the pressure of active materials typically found in cosmetic compositions.

Abstract: Materials and methods are provided for preventing and dispersing biofilms. Methods and compositions are described for preventing and treating dental caries. Materials and methods are provided for producing antibiofilm agents from natural products, including maple (Acer sp.). Compositions are provided for inhibiting Sortase A activity in Bacillota.

Abstract: Cleansing dye compositions are disclosed. In embodiments, a cleansing dye composition may include, based on a total weight of the cleansing dye composition, greater than or equal to 0.0001 wt % and less than or equal to 10 wt % of at least one direct dye; and greater than 15 wt % and less than or equal to 50 wt % of at least one cyclic saccharide-derived surfactant having a total surfactant activity level greater than 7.5 wt % and less than or equal to 25 wt %.

Abstract: A skin care composition for suppressing formation of wrinkles caused by photoaging, wherein the composition contains at least one pyrimidine nucleotide or a precursor thereof as an active ingredient.

Abstract: The present disclosure relates to cosmetic compositions and related methods of use. The cosmetic compositions can act as a lash serum, primer, and mascara all in one. The cosmetic compositions include a mixture of peptides and vitamins, including myristoyl pentapeptide-1 and biotinoyl tripeptide-1.

Abstract: This disclosure provides a protein oleogel comprising plant protein dispersed in a liquid oil phase. The oleogel has a microstructure in the form of fibrils, sheets, or other particles with a high aspect ratio that are substantially not interconnected. It can be manufactured by a process that includes solubilizing and denaturing the protein in an aqueous liquid, flash freezing and drying the protein, and then gradually and gently adding a suitable oil or oil mixture. The protein microstructure releases some but not all of the oil when heated. The oleogel forms a spreadable emulsion in an aqueous liquid that is stable for at least six weeks without evidence of creaming. The oleogel may substitute for oils and fats of animal origin in food, food ingredients, cosmetics, and personal care products. This lessens the impact of food manufacturing on the environment, which helps mitigate climate change.

Abstract: The present invention relates to a cosmetic compound comprising a eutectic mixture containing vitamin C and betaine and a preparation method therefor and can provide a cosmetic composition that contains vitamin C in the form of a eutectic mixture and thus exhibits high solubility in various types of solvents, excellent oxidation stability, and high skin permeability.

Abstract: A water-soluble lignin obtained by enzymatic treatment, the lignin being water-soluble at a pH between 5 and 10, as an anti-UV filter. A cosmetic composition including the lignin.

Abstract: The present invention relates to an antimicrobial composition, more particularly to a method and a composition to prevent or mitigate bodily malodour, especially present in human axilla. This is achieved by a composition that comprises a vitamin B3 compound or derivative thereof along with pectin.

Abstract: A composition for use as a lip liner, the composition including a solvent that evaporates substantially independently of a user's skin, one or more colorants that stain the user's skin, the one or more colorants being dissolved in the solvent, and a film-forming agent that forms a film over a surface of the lip liner as the solvent evaporates, the film-forming agent being dissolved in the solvent, the film being configured to adhere to the user's skin, the film being configured to be peeled off of the user's skin once the solvent has evaporated.

Abstract: Disclosed is a foaming composition, comprising: (a) at least one oil. (b) at least one polymeric interface stabilizer of improving rheology of the composition and boosting and stabilizing the foams formed therein, and (c) a surfactant system, comprising, substantially consisting of, or even consisting of at least one alkyl sulfosuccinate, at least one amphoteric surfactant, and optionally, at least one nonionic surfactant.

Abstract: The present invention relates generally to methods and compositions useful for defining the appearance of eyelashes and increasing the length of eyelashes. The composition comprises 3 to 50% by weight of water based on a total weight of the composition; 5 to 20% by weight of a combination of waxes based on the total weight of the composition, wherein the combination of waxes comprises paraffin wax, polyethylene, and carnauba wax; 4 to 15% by weight of a combination of film forming agents based on the total weight of the composition, wherein the combination of film forming agents comprises vinylpyrrolidone (VP)/eicosene copolymer and triacontanyl polyvinylpyrrolidone (PVP); 5 to 15% iron oxides based on the total weight of the composition; silica; tocopheryl acetate; and panthenol.

Abstract: Methods for enhancing skin resistance, improving skin smoothness, or improving skin brightness are provided. The method includes administering to a subject in need thereof a composition containing Ampelopsis grossedentata leaf extract. The Ampelopsis grossedentata leaf extract is obtained by extracting leaves of Ampelopsis grossedentata with water at 85±5° C. for 50-70 min.

Abstract: The present disclosure is directed to hair care compositions, including at least one organic acid, at least one compound with at least one hydroxyl-group, at least one amino acid, at least one vegetal resin, and water. The present disclosure is also related to a method of treating hair, particularly curly hair.

Abstract: The present invention relates generally to compositions for a topical composition comprising Myrothamnus flabellifolia extract, saccharide isomerate extract, Alteromonas ferment extract and/or Opuntia tuna fruit extract. The present invention further relates to methods of using the compositions to improve skin appearance and skin conditions.

Abstract: A sustained release composition for oral administration comprises a physiologically active ingredient mixed with a methylcellulose, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages and wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that the s23/s26 is more than 0.27, and wherein the concentration of methylcellulose is from 0.1 to 10% by dry weight of the active ingredient.

Abstract: A transdermal formulation for the delivery of one or more active agents to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions associated with an elevated CD38 level.

Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acid. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agents, a penetration enhancer, and an emulsifier.

Abstract: Compositions and related kits and methods for treating a target site of a patient are described herein. The composition may include a hemostatic agent and a pH agent, for example. Methods of treatment include delivering and applying the hemostatic agent and the pH agent to a gastrointestinal system of a patient via a medical device to reduce bleeding of tissue in the gastrointestinal system.

Abstract: A drug delivery device comprising, a first body part, an attachment part attached to the first body part, a second body part, an aperture in the first body part and/or the second body part, an actuator mechanism configured to store energy and convert the stored energy to kinetic energy via movement of the first body part or the second body part, and a locking system configured to prevent the actuator mechanism from converting the stored energy to the kinetic energy.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: A use of perilla in the manufacture of a medicament for inhibition of Coronavirus disease 2019 (COVID-19) virus is provided. Perilla is treatment by ultrafine pulverization and wall-breaking to obtain perilla micropowder with a particles size of 6000 mesh. The perilla micropowder is used in the manufacture of an inhibitor of COVID-19 virus (SARS-COV-2,Omincron variant) and a medicament for treatment, prevention, or relief of diseases caused by COVID-19 virus (SARS-COV-2,Omincron variant).

Abstract: Gastric residence systems for administration of risperidone are disclosed. Features which enhance gastric retention during the desired residence time and which allow for more precise control over residence time are disclosed, including circumferential filaments connecting the arms of a stellate gastric residence system; improved time-dependent and enteric disintegrating matrices (linkers); and release rate-modulating polymer coatings which are resistant to change in release rate properties during heat-assisted assembly or thermal cycling. Combinations of these features are also disclosed.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: A pharmaceutical composition for dry powder inhalation includes an active ingredient and a first pharmacologically acceptable excipient. The active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmacologically acceptable excipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof. A method of preparing a pharmaceutical composition for dry powder inhalation is also provided.

Abstract: A method for treating obesity associated with Prader Willi Syndrome is disclosed.

Abstract: The present invention relates to a biodegradable odontostomatological scaffold with disinfectant properties and comprising a three-dimensional gel of hyaluronic acid and to the use thereof in the disinfection, healing and regeneration of oral tissues.

Abstract: Disclosed in the present invention is a Ruxolitinib composition, comprising: Ruxolitinib or a pharmaceutically acceptable salt, an emulsifier, a co-emulsifier, a solvent, and an aqueous phase thereof. The emulsifier comprises one or more of polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil and vitamin E succinic acid. The co-emulsifier comprises propylene glycol monocaprylate. The solvent comprises one or more of propylene glycol, diethylene glycol monoethyl ether, and ethanol. The Ruxolitinib composition of the present invention has an ideal particle size and PDI. Furthermore, the present invention provides Ruxolitinib gel. Compared with a Ruxolitinib cream, the film-permeable efficiency is improved, and the stability of administration to the external skin under the condition of pH 5-7 can be satisfied; compared with the Ruxolitinib cream, as well as commercially available calcipotriol and Benvitimod, the present invention achieves a better drug effect in the aspect of psoriasis treatment.

Abstract: The present disclosure relates to stable oral liquid pharmaceutical formulations comprising trazodone or its pharmaceutically acceptable salts thereof, one or more sweeteners, one or more preservatives and water. The formulations of the present disclosure are palatable, alcohol-free, freeze-thaw stable, and buffer-free. The present disclosure further relates to method of treatment of major depressive disorder comprising administering to the subject in need thereof stable oral liquid pharmaceutical formulation comprising trazodone or its pharmaceutically acceptable salts thereof, one or more sweeteners, one or more preservatives and water.

Abstract: The present invention relates to A solvent-free process for making a nanodispersion delivery system comprising emulsifying mixing fat soluble vitamins or nutraceuticals with miscible food grade lipids at a temperature of between 60-100° C. to obtain a lipid mixture, homogenizing said lipid mixture with a mixture of surfactants to form a coarse emulsion, downsizing said coarse emulsion to nanodispersion using ultrasonication or high pressure homogenization, and mixing said nanodispersion with shell/coating materials and spray drying.

Abstract: There are provided novel topical or transdermal nano-formulations of diclofenac. The formulations are in the form of micellar solutions. The micellar solutions comprise diclofenac alkali metal salt, in a concentration of about 2% to about 5.5% (w/w), a solvent, a mixture of surfactants, and an aqueous continuous, outer phase. The micellar solution may optionally further comprise permeation enhancers. The micellar solutions can be gelled with a suitable gelling agent. The compositions disclosed are useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and/or inflammation.

Abstract: It is a known fact that when fine water having a particle size of 50 nanometers or less enters the horny layer of the skin, the fine water softens the skin and expands gaps in the horny layer. Therefore, when being used for perfumes or cosmetics, skin external preparations, or the like, lipid membrane vesicles containing the fine water are allowed to easily enter the horny layer.

Abstract: Lipocoacervates and compositions comprising lipocoacervates, methods of making and using same. A lipocoacervate comprises a coacervate phase and a lipid or lipids, where the lipid(s) is/are disposed on at least a portion of an exterior surface of the coacervate phase, and optionally, one or more biomolecules. In various examples, a coacervate phase comprises cationic component(s), such as, for example, polycations, such as, for example, chitosan, spermine, spermidine, positively-charged polymers, positively-charged proteins, and any combination thereof, and anionic component(s), such as, for example, polyanions, such as, for example, glycosaminoglycans, nucleic acids, negatively-charged proteins, and any combination thereof. In various examples, an anionic component is a biomolecule. In various examples, a lipocoacervate is made by contacting a coacervate composition with a lipid composition, where lipocoacervate(s) or a lipocoacervate composition is/are formed.

Abstract: Liposomes, and pharmaceutical compositions comprising same, for use in treating biofilm in a subject in need thereof are disclosed herein. The liposomes comprise a bilayer-forming lipid; a polymer-lipid conjugate having the general formula I, as described and defined in the specification; a positively-charged lipidic agent, incorporated within a lipid bilayer and/or on a surface of the liposome; and a therapeutically active agent, bound to a surface of the liposome and/or within a lipid bilayer and/or core of the liposome.

Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.

Abstract: The application relates to ionizable lipids. The formulations of ionizable lipids can be used for the delivery of one or more nucleic acid therapeutic agents, for example mRNA, siRNA or miRNA. The compositions can include additional lipids, such as non-cationic lipids, PEG-modified lipids and optionally cholesterol.

Abstract: The present disclosure relates to a process for manufacturing an oral pharmaceutical dosage form including: mixing an active pharmaceutical ingredient (API) and surfactant into a blend; feeding the blend into a processor that applies heat and shear forces at a temperature within a range of approximately equal to the melting point of the surfactant to 3° C. below the melting point of the surfactant so as to form API granulates; and formulating the API granulates into a dosage form. The disclosed technology provides a surprisingly effective and economical means for producing high dose solid dosage forms containing poorly soluble APIs with minimal excipient burden.

Abstract: This disclosure pertains to methods to prepare coated particles comprising a drug-containing core and a coating of inorganic oxides applied by vapor phase deposition (supercycles). The coated particles have a modified drug release profile comparing to the uncoated drug particles.

Abstract: Provided herein are high throughput methods for optimizing and manufacturing various lipid nanoparticle (LNP) compositions and uses thereof. In some embodiments, the present disclosure provides a high-throughput screening method for manufacturing a LNP composition comprising, obtaining at least two intermixable solutions comprising a payload and a plurality of molecules capable of self-assembly, and mixing said at least two solutions under a set of controlled conditions, by which injection sequence, speed, volume, phase ratio and mixing duration are varied. In various embodiments, the present disclosure enables optimal encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability to be determined. The methods disclosed herein enable efficient optimization of manufacturing conditions for preparation of LNP-based therapeutics.

Abstract: The present disclosure provides transdermal drug delivery systems, methods, and platforms. In one example, the smart patch includes a drug-containing layer, a communication interface, and one or more sensors configured to detect a status change of the smart patch to the smart patch, the status change of the smart patch including one or more of removing a packaging from the smart patch and applying the smart patch to skin of the patient. The smart patch further includes a processor communicatively coupled to the one or more sensors and the communication interface, wherein the processor is configured to perform operations including automatically transiting between a plurality of working conditions based on the status change of the smart patch, the plurality of working conditions of the smart patch comprising a hibernation mode, a sleep mode, and a work mode and transmitting smart patch usage data via the communication interface.

Abstract: A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

Abstract: The invention provides novel iso-osmotic or near iso-osmotic formulations of fluorocarbon emulsions that are useful as oxygen therapeutics, for example, for treating sickle cell disease and related diseases and conditions, as well as methods of preparation and use thereof.